Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Enanta Pharmaceuticals, Inc. ENTA
$25.08
-$0.43 (-1.72%)
На 18:00, 12 мая 2023
+161.84%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
530723424.00000000
-
week52high
76.36
-
week52low
23.03
-
Revenue
86160000
-
P/E TTM
-6
-
Beta
0.38200600
-
EPS
-5.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Perform | Perform | 10 авг 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 09 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 09 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 01 авг 2022 г. |
| Oppenheimer | Perform | Perform | 01 авг 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 22 ноя 2022 г. |
| HC Wainwright & Co. | Buy | 09 дек 2022 г. | |
| SVB Leerink | Market Perform | Market Perform | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MELLETT PAUL J | D | 0 | 2812 | 09 янв 2023 г. |
| MELLETT PAUL J | A | 88463 | 2812 | 09 янв 2023 г. |
| Luly Jay R. | D | 55500 | 14500 | 19 дек 2022 г. |
| Luly Jay R. | A | 788305 | 14500 | 19 дек 2022 г. |
| MELLETT PAUL J | D | 0 | 4148 | 19 дек 2022 г. |
| MELLETT PAUL J | A | 85651 | 4148 | 19 дек 2022 г. |
| Luly Jay R. | D | 27912 | 13851 | 16 дек 2022 г. |
| Luly Jay R. | D | 0 | 16149 | 16 дек 2022 г. |
| Luly Jay R. | D | 773805 | 13603 | 16 дек 2022 г. |
| Luly Jay R. | D | 787408 | 8597 | 16 дек 2022 г. |
Новостная лента
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:03
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $1.63 per share a year ago.
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
Business Wire
08 мар 2023 г. в 08:51
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Business Wire
07 мар 2023 г. в 07:00
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2023 Earnings Call Transcript
Seeking Alpha
07 февр 2023 г. в 22:12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q1 2023 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Jennifer Viera – Investor Relations Jay Luly – President and Chief Executive Officer Paul Mellett – Chief Financial Officer Tara Kieffer – Senior Vice President-New Product Strategy Development Conference Call Participants Joe Kim – RBC Luke Herrmann – Baird Roanna Ruiz – SVB Securities Matthew Hershenhorn – Oppenheimer Ed Arce – H.C. Wainwright & Co Eric Joseph – JPMorgan Roy Buchanan – JMP Securities Operator Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal First Quarter Ended December 31, 2022 Financial Results Conference Call.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
07 февр 2023 г. в 18:49
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 8.55% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?